Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | CMA1 | P23946 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25650691 | 0.86 | CTSV (0.46) | CTSVCTSLCTSBELANECMA1 | |
| SCHEMBL25757795 | 0.86 | CTSV (0.46) | CTSVCTSLCTSBELANECMA1 | |
| SCHEMBL14513459 | 0.84 | ELANE (0.40) | CTSVCTSLCTSBELANECMA1 | |
| SCHEMBL25650737 | 0.84 | CTSV (0.46) | CTSVCTSLCTSBELANECMA1 | |
| SCHEMBL25757804 | 0.82 | CTSV (0.45) | CTSVCTSLCTSBELANECMA1 | |
| SCHEMBL13605066 | 0.80 | CTSV (0.36) | CTSVCTSLCTSBELANECMA1 | |
| SCHEMBL8283446 | 0.79 | CTSV (0.38) | CTSVCTSLCTSBELANECMA1 | |
| SCHEMBL24486605 | 0.77 | CTSV (0.40) | CTSVCTSLCTSBELANECMA1 | |
| SCHEMBL30556853 | 0.76 | CTSV (0.45) | CTSVCTSLCTSBELANECMA1 | |
| SCHEMBL30556789 | 0.75 | CTSV (0.46) | CTSVCTSLCTSBELANECMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023114516-A2 | CELL-PERMEANT INHIBITORS OF VIRAL CYSTEINE PROTEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-06-22 | — | — | WO | disclosed |